Genes & biomarkers

FGFR2 fusions and rearrangements

FGFR2 · fusion / rearrangement

FGFR2 fusions/rearrangements are targets in some bile duct cancers.

Sources checked · Introductory guide

On this page

What does this result mean?

FGFR2 encodes a growth-signaling receptor. Structural changes, including joining to another gene, can be important in bile duct cancer.[1]

How does it connect to treatment?

Pemigatinib is used in selected previously treated bile duct cancers with FGFR2 fusions/rearrangements. Other FGFR2 variants or changes in another FGFR gene do not automatically qualify.[2]

What should I check in my report?

Check whether a fusion/rearrangement was confirmed, rather than amplification or a VUS. Review operability and previous treatment as well.

Questions for your care team

  • Is my FGFR2 finding a qualifying fusion/rearrangement for bile duct treatment?
  • Which treatments or trials fit my cancer type, stage and previous treatment?

Sources and scope

Source documents are in English.

Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.

  1. MedlinePlus Genetics · FGFR2 (opens in a new tab)
  2. NCI · pemigatinib (opens in a new tab)

General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.

Related entries

FGFR2 fusions and rearrangements | Cancer Encyclopedia | My Chemo Diary